Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

PARATEK PHARMACEUTICALS, INC.

(PRTK)
  Report
Delayed Nasdaq  -  04:00:01 2023-02-06 pm EST
2.150 USD   -3.59%
02/01Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
AQ
01/18Paratek Pharmaceuticals Says Nuzyra Added to China's National Reimbursement Drug List
MT
01/18Paratek Pharmaceuticals Announces Inclusion of NUZYRA« (omadacycline) in China's National Reimbursement Drug List (NRDL)
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

12/01/2022 | 05:46pm EST

BOSTON, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use, today announced that on November 30, 2022, the Company granted restricted stock units to one new employee of the Company. This award was granted pursuant to the Paratek Pharmaceuticals, Inc. 2017 Inducement Plan, as amended, which was approved by the Company's board of directors on June 15, 2017, under Rule 5635(c)(4) of the NASDAQ Listing Rules, for equity grants to employees entering into employment or returning to employment after a bona fide period of non-employment with the Company, as an inducement material to such individuals entering into employment with the Company.   

The restricted stock units are to acquire, in the aggregate, 4,900 shares of the Company’s common stock and shall vest upon the conclusion of a 36-month vesting period, under which one hundred percent 100% of the restricted stock units will vest after 36 months of employment, subject to the employee’s continuous service. The restricted stock units are subject to the terms and conditions of the Paratek Pharmaceuticals, Inc. 2017 Inducement Plan, as amended, and the terms and conditions of the restricted stock unit award agreement covering each grant.

About Paratek Pharmaceuticals, Inc.
Paratek Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use. 

The company’s lead commercial product, NUZYRA® (omadacycline), is a once-daily oral and intravenous antibiotic available in the United States for the treatment of adults with community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI). Paratek has a collaboration agreement with Zai Lab for the development and commercialization of omadacycline in the greater China region and retains all remaining global rights.

Paratek is also conducting a Phase 2b Study in a rare disease, nontuberculous mycobacterial (NTM) pulmonary disease, caused by Mycobacterium abscessus complex with NUZYRA. Paratek estimates this opportunity represents a potential $1 billion addressable market in the United States. 

Paratek exclusively licensed U.S. rights and rights to the greater China territory for SEYSARA® (sarecycline), a once-daily oral therapy for the treatment of moderate to severe acne vulgaris, to Almirall, LLC. Paratek retains the development and commercialization rights for sarecycline in the rest of the world.

In 2019, Paratek was awarded a contract from the U.S. Department of Health and Human Services’ Biomedical Advanced Research and Development Authority (BARDA), now valued at up to approximately $304 million, to support the development and U.S.-based manufacturing of NUZYRA for pulmonary anthrax.

For more information, visit www.ParatekPharma.com or follow us on LinkedIn and Twitter.

CONTACT:           

For Investors:                   
Hans Vitzthum
LifeSci Advisors
ir@ParatekPharma.com
Phone: 617-430-7578                    

For Media:
Christine Fanelle
Scient PR
christine@scientpr.com
Phone: 215-595-5211        


Primary Logo

Source: Paratek Pharmaceuticals

2022 GlobeNewswire, Inc., source Press Releases

All news about PARATEK PHARMACEUTICALS, INC.
02/01Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
AQ
01/18Paratek Pharmaceuticals Says Nuzyra Added to China's National Reimbursement Drug List
MT
01/18Paratek Pharmaceuticals Announces Inclusion of NUZYRA« (omadacycline) in China's Nation..
AQ
01/18Paratek Pharmaceuticals, Inc. Announces Inclusion of NUZYRA(R) (omadacycline) in China'..
CI
01/05Paratek Pharmaceuticals Gets $36.4 Million Milestone Payment From Second Procurement of..
MT
01/05Paratek Pharmaceuticals Receives $36.4 Million Milestone Payment Associated with the Se..
AQ
01/05Paratek Pharmaceuticals Receives $36.4 Million Payment Associated with the Second Procu..
CI
2022Paratek Pharmaceuticals Appoints Jeffrey Stein as Lead Independent Director of the Boar..
AQ
2022Paratek Pharmaceuticals, Inc. Appoints Jeffrey Stein as First Lead Independent Director
CI
2022Paratek Pharmaceuticals Says Positive Data From Nuzyra Study to Treat Anthrax Triggers ..
MT
More news
Analyst Recommendations on PARATEK PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2022 148 M - -
Net income 2022 -50,6 M - -
Net Debt 2022 - - -
P/E ratio 2022 -2,11x
Yield 2022 -
Capitalization 119 M 119 M -
Capi. / Sales 2022 0,81x
Capi. / Sales 2023 0,51x
Nbr of Employees 208
Free-Float 83,4%
Chart PARATEK PHARMACEUTICALS, INC.
Duration : Period :
Paratek Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PARATEK PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 2
Last Close Price 2,15 $
Average target price 19,67 $
Spread / Average Target 815%
EPS Revisions
Managers and Directors
Evan Loh Chief Executive Officer & Director
Adam Woodrow President & Chief Commercial Officer
Sarah Higgins VP, Chief Financial & Accounting Officer
Michael F. Bigham Executive Chairman
Raj Padmanabhan Vice President-Information Technology
Sector and Competitors
1st jan.Capi. (M$)
PARATEK PHARMACEUTICALS, INC.14.97%119
JOHNSON & JOHNSON-6.82%427 102
ELI LILLY AND COMPANY-7.31%320 837
NOVO NORDISK A/S2.13%311 923
ROCHE HOLDING AG-2.27%269 272
MERCK & CO., INC.-6.24%263 757